Copyright
©The Author(s) 2023.
World J Gastroenterol. May 7, 2023; 29(17): 2551-2570
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2551
Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2551
Table 3 Clinical trials under investigation
Drugs | Mechanisms | Clinical trials |
Anakinra and Canakinumab | Reduce hepatic inflammation | NCT01809132[121], NCT04072822[122], NCT03775109[123] |
N-acetyl cysteine, S-adenosyl methionine (SAM-E) | Reduce oxidative stress | NCT03069300[124], NCT00851981[125], NCT02024295[126] |
DUR-928 | Epigenetic modulation of lipid homeostasis, inflammation, cell survival, tissue regeneration | NCT03432260[127], NCT03917407[128] |
Granulocyte colony stimulating growth factors, interleukin-22 and obeticholic acid | Boosts liver regeneration | NCT02442180[129], NCT03703674[130], NCT04066179[131], NCT02655510[132], NCT01918462[133], NCT02039219[134] |
Rifaximin, zinc supplementation, bovine colostrum, probiotics, and fecal microbiota transplant | Targets the gut-liver axis | NCT02116556[135], NCT02485106[136], NCT01968382[137], NCT02473341[138], NCT01922895[139], NCT02335632[140], NCT02458079[141], NCT03091010[142], NCT03827772[143] |
- Citation: Chaudhry H, Sohal A, Iqbal H, Roytman M. Alcohol-related hepatitis: A review article. World J Gastroenterol 2023; 29(17): 2551-2570
- URL: https://www.wjgnet.com/1007-9327/full/v29/i17/2551.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i17.2551